Log in

Relevant bibliographies by topics / Intranasal administration of dopamine / Journal articles

To see the other types of publications on this topic, follow the link: Intranasal administration of dopamine.

Journal articles on the topic 'Intranasal administration of dopamine'

Author: Grafiati

Published: 5 June 2025

Last updated: 16 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Intranasal administration of dopamine.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Dagda, Ruben K., Raul Y. Dagda, Emmanuel Vazquez-Mayorga, Bridget Martinez, and Aine Gallahue. "Intranasal Administration of Forskolin and Noopept Reverses Parkinsonian Pathology in PINK1 Knockout Rats." International Journal of Molecular Sciences 24, no. 1 (2022): 690. http://dx.doi.org/10.3390/ijms24010690.

Full text

Abstract:

Parkinson’s Disease (PD) is a brain-degenerative disorder characterized by a progressive loss of midbrain dopamine neurons. Current standard-of-care includes oral administration of Levodopa to address motor symptoms, but this treatment is not disease-modifying. A reduction in Protein Kinase A (PKA) signaling and neurotrophic support contributes to PD pathology. We previously showed that enhancing PKA activity in the brain via intraperitoneal administration of Forskolin in Parkinsonian rats (PINK1 knockout) abrogate motor symptoms and loss of midbrain dopamine neurons. Given that intraperitonea

APA, Harvard, Vancouver, ISO, and other styles

2

Nedorubov, Andrey Anatolievich, Alexey Nikitich Pavlov, Natalia Valeryevna Pyatigorskaya, Galina Eduardovna Brkich, and Marina Maksimovna Shabalina. "Pharmacokinetics of Nanosomal Form of Levodopa in Intranasal Administration." Open Access Macedonian Journal of Medical Sciences 7, no. 21 (2019): 3509–13. http://dx.doi.org/10.3889/oamjms.2019.749.

Full text

Abstract:

BACKGROUND: Parkinson's disease is one of the most common neurological diseases. Pathogenesis of the disease is associated with destruction and death of neurons that produce the neurotransmitter dopamine. The precursor to dopamine, which crosses the protective blood-brain barrier, is the amino acid 3, 4-dihydroxy-L-phenylalanine – levodopa, L-DOPA. The investigational drug is a pharmaceutical composition, containing L-DOPA as an active substance, which is distributed in a polymer matrix based on a biodegradable copolymer of lactic/glycolic acids. AIM: This work aimed to study the main ph

APA, Harvard, Vancouver, ISO, and other styles

3

Amikishieva, A., and A. Cholodar. "P.1.c.066 Behavioural effects of intranasal dopamine administration." European Neuropsychopharmacology 20 (August 2010): S273. http://dx.doi.org/10.1016/s0924-977x(10)70353-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Cox, Sylvia M. L., Chawki Benkelfat, Alain Dagher, et al. "Striatal Dopamine Responses to Intranasal Cocaine Self-Administration in Humans." Biological Psychiatry 65, no. 10 (2009): 846–50. http://dx.doi.org/10.1016/j.biopsych.2009.01.021.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Levicheva, N. O., O. G. Berchenko, and Y. Y. Ilina. "Effect of Intranasal Administration of Dopamine on Odor Perception in Rats with Nigrostriatal Dysfunction." Ukraïnsʹkij žurnal medicini, bìologìï ta sportu 6, no. 3 (2021): 333–39. http://dx.doi.org/10.26693/jmbs06.03.333.

Full text

Abstract:

In recent years, there has been a growing interest in finding early predictors of Parkinson’s disease. In this regard, it is worth noting the olfactory dysfunction, which is associated with the death of neurons in the structures of the limbic system of the brain and a decrease in dopamine levels in the striatum. It was found that most patients with Parkinson’s disease have a clear olfactory dysfunction in the form of impaired differentiation and identification of odors. It has been suggested that the use of low doses of dopamine in the early stages of Parkinson’s disease will stop the progress

APA, Harvard, Vancouver, ISO, and other styles

6

Mizutani, Asuka, Masato Kobayashi, Makoto Ohuchi, et al. "Indirect SPECT Imaging Evaluation for Possible Nose-to-Brain Drug Delivery Using a Compound with Poor Blood–Brain Barrier Permeability in Mice." Pharmaceutics 14, no. 5 (2022): 1026. http://dx.doi.org/10.3390/pharmaceutics14051026.

Full text

Abstract:

Single-photon emission computed tomography (SPECT) imaging using intravenous radioactive ligand administration to indirectly evaluate the time-dependent effect of intranasal drugs with poor blood-brain barrier permeability on brain drug distributions in mice was evaluated. The biodistribution was examined using domperidone, a dopamine D2 receptor ligand, as the model drug, with intranasal administration at 0, 15, or 30 min before intravenous [123I]IBZM administration. In the striatum, [123I]IBZM accumulation was significantly lower after intranasal (IN) domperidone administration than in contr

APA, Harvard, Vancouver, ISO, and other styles

7

Sergeyeva, T. N., and K. S. Sergeyeva. "EFFECTS OF INTRANASAL BACTERIAL ENDOTOXIN ADMINISTRATION ON EXPRESSION OF ALPHA-SYNUCLEIN IN PERIPHERAL STRUCTURES OF THE OLFACTORY SYSTEM." Medical academic journal 19, no. 1S (2019): 103–4. http://dx.doi.org/10.17816/maj191s1103-104.

Full text

Abstract:

The involvement of olfactory dysfunction led to the proposal of ‘the olfactory vector hypothesis’ to explain both olfactory losses and the etiology of idiopathic Parkinson disease (PD) as a result of the transit of an environmental virus or chemical agent that enters the central nervous system (CNS) via the nose, activating the glial response of the brain that may lead to dopamine neuronal damage. Previously created chronic, progressive a mouse model of PD by intranasal instillation of a LPS displayed several key features of early-stage PD: a progressive hypokinesia, selective loss of dopamine

APA, Harvard, Vancouver, ISO, and other styles

8

Geiko, Valentina, and Olga Berchenko. "Correction of the wake-sleep cycle by intranasal administration of dopamine in modeling of the preclinical stage of Parkinson's disease in rats." EUREKA: Life Sciences, no. 5 (November 16, 2022): 47–57. https://doi.org/10.21303/2504-5695.2022.002643.

Full text

Abstract:

Sleep disorders, which are among the earliest and most sensitive non-motor manifestations of Parkinson's disease (PD), are not diagnosed in 40–50 % of patients and are not subject to the necessary correction. In this regard, the ineffectiveness of a late start of treatment, when more than 50 % of dopamine-producing neurons are already affected, dictates the need to search for and develop approaches to the prevention and slowdown of neurodegenerative pathology at the preclinical stages of its development using adequate experimental models. Taking into account the low bioavailability of dopamine

APA, Harvard, Vancouver, ISO, and other styles

9

Geiko, Valentina, and Olga Berchenko. "Correction of the wake-sleep cycle by intranasal administration of dopamine in modeling of the preclinical stage of Parkinson's disease in rats." EUREKA: Life Sciences, no. 5 (November 16, 2022): 47–57. http://dx.doi.org/10.21303/2504-5695.2022.002643.

Full text

Abstract:

Sleep disorders, which are among the earliest and most sensitive non-motor manifestations of Parkinson's disease (PD), are not diagnosed in 40–50 % of patients and are not subject to the necessary correction. In this regard, the ineffectiveness of a late start of treatment, when more than 50 % of dopamine-producing neurons are already affected, dictates the need to search for and develop approaches to the prevention and slowdown of neurodegenerative pathology at the preclinical stages of its development using adequate experimental models. Taking into account the low bioavailability of dopamine

APA, Harvard, Vancouver, ISO, and other styles

10

Lao, Chu Lan, Yen-Hsi Kuo, Yueh-Ting Hsieh, and Jin-Chung Chen. "Intranasal and Subcutaneous Administration of Dopamine D3 Receptor Agonists Functionally Restores Nigrostriatal Dopamine in MPTP-Treated Mice." Neurotoxicity Research 24, no. 4 (2013): 523–31. http://dx.doi.org/10.1007/s12640-013-9408-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Md, Shadab, Shahid Karim, Sanggetha R. Saker, et al. "Current Status and Challenges in Rotigotine Delivery." Current Pharmaceutical Design 26, no. 19 (2020): 2222–32. http://dx.doi.org/10.2174/1381612826666200316154300.

Full text

Abstract:

Rotigotine is a non-ergoline, high lipophilic dopamine agonist. It is indicated as the first-line therapy for Parkinson&#039;s disease (PD) and Restless Leg Syndrome (RLS). However, the precise mechanism of rotigotine is yet to be known. Rotigotine has similar safety and tolerability to the other oral non-ergolinic dopamine antagonists in clinical trials, which include nausea, dizziness and somnolence. Neupro® was the first marketed transdermal patch formulation having rotigotine. The transdermal delivery system is advantageous as it enables continuous administration of the drug, thus prov

APA, Harvard, Vancouver, ISO, and other styles

12

Trapani, Adriana, Elvira De Giglio, Stefania Cometa, et al. "Dopamine-loaded lipid based nanocarriers for intranasal administration of the neurotransmitter: A comparative study." European Journal of Pharmaceutics and Biopharmaceutics 167 (October 2021): 189–200. http://dx.doi.org/10.1016/j.ejpb.2021.07.015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Nikitina, Alexandra A., Svetlana G. Belokoskova, Victoria A. Maystrenko, et al. "The participation of monoamines in the realization of vasopressin analgesic effects during electrical stimulation of paws in rats." Medical academic journal 24, no. 2 (2024): 45–52. http://dx.doi.org/10.17816/maj633203.

Full text

Abstract:

BACKGROUND: Arginine vasopressin has been implicated in the modulation of stress and pain. The influence of a synthetic analogue of arginine vasopressin, 1-deamino-8-D-arginine-vasopressin, оn pain sensitivity, stress reactivity, levels of monoamines and brain neurotrophic factor in a model of paw electrical stimulation in rats has not been studied. AIM: The aim was to evaluate the effect of a synthetic vasopressin analog, 1-deamino-8-D-arginine-vasopressin, on pain sensitivity and the content of norepinephrine, serotonin, dopamine, brain neurotrophic factor in the parietal cortex and spinal c

APA, Harvard, Vancouver, ISO, and other styles

14

Berchenko, O. G., A. V. Shliakhova, O. V. Veselovska, A. M. Titkova, and N. O. Levicheva. "PROGESTERONE MODULATION OF ANXIETY AND DOPAMINERGIC MESOLIMBIC SYSTEM OF THE BRAIN ACTIVITY IN RATS WITH ALCOHOL DEPENDENCE AND UNDER CONDITIONS OF ZOOSOCIAL CONFLICT." Fiziolohichnyĭ zhurnal 69, no. 5 (2023): 43–50. http://dx.doi.org/10.15407/fz69.05.043.

Full text

Abstract:

Exogenous modulation by progesterone of the central neurosteroid mechanisms of regulation of anxiety and its important component, the activity of the mesolimbic dopaminergic system, is a promising method of correction of emotional behavioral disorders. The aim of this work was to study the effect of intranasal progesterone administration on the baseline level of anxiety and the activity of the dopaminergic mesolimbic brain system in alcohol-dependent and zoosocial conflict rats. Neuroethological studies by the method of assessing the individual level of anxiety. The levels of catecholamines (d

APA, Harvard, Vancouver, ISO, and other styles

15

Kholodar, A. V., A. V. Amikishieva, and M. P. Anisimov. "Effects of Intranasal Administration of Dopamine on Anxiety and Locomotor Activity in Two Mouse Strains." Neuroscience and Behavioral Physiology 43, no. 3 (2013): 409–15. http://dx.doi.org/10.1007/s11055-013-9747-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Yu-Taeger, Libo, Janice Stricker-Shaver, Katrin Arnold, et al. "Intranasal Administration of Mesenchymal Stem Cells Ameliorates the Abnormal Dopamine Transmission System and Inflammatory Reaction in the R6/2 Mouse Model of Huntington Disease." Cells 8, no. 6 (2019): 595. http://dx.doi.org/10.3390/cells8060595.

Full text

Abstract:

Intrastriatal administration of mesenchymal stem cells (MSCs) has shown beneficial effects in rodent models of Huntington disease (HD). However, the invasive nature of surgical procedure and its potential to trigger the host immune response may limit its clinical use. Hence, we sought to evaluate the non-invasive intranasal administration (INA) of MSC delivery as an effective alternative route in HD. GFP-expressing MSCs derived from bone marrow were intranasally administered to 4-week-old R6/2 HD transgenic mice. MSCs were detected in the olfactory bulb, midbrain and striatum five days post-de

APA, Harvard, Vancouver, ISO, and other styles

17

Pazi, Maria B., Daria V. Belan, Elena Y. Komarova, and Irina V. Ekimova. "Intranasal Administration of GRP78 Protein (HSPA5) Confers Neuroprotection in a Lactacystin-Induced Rat Model of Parkinson’s Disease." International Journal of Molecular Sciences 25, no. 7 (2024): 3951. http://dx.doi.org/10.3390/ijms25073951.

Full text

Abstract:

The accumulation of misfolded and aggregated α-synuclein can trigger endoplasmic reticulum (ER) stress and the unfolded protein response (UPR), leading to apoptotic cell death in patients with Parkinson’s disease (PD). As the major ER chaperone, glucose-regulated protein 78 (GRP78/BiP/HSPA5) plays a key role in UPR regulation. GRP78 overexpression can modulate the UPR, block apoptosis, and promote the survival of nigral dopamine neurons in a rat model of α-synuclein pathology. Here, we explore the therapeutic potential of intranasal exogenous GRP78 for preventing or slowing PD-like neurodegene

APA, Harvard, Vancouver, ISO, and other styles

18

Shahien, Mona M., Alia Alshammari, Somaia Ibrahim, et al. "Development of Glycerosomal pH Triggered In Situ Gelling System to Ameliorate the Nasal Delivery of Sulpiride for Pediatric Psychosis." Gels 10, no. 9 (2024): 608. http://dx.doi.org/10.3390/gels10090608.

Full text

Abstract:

Sulpiride (Sul) is a medication that blocks dopamine D2 receptors. It is used to treat gastrointestinal disturbances and has antipsychotic effects depending on the dose given. Sulpiride is subject to P-glycoprotein efflux, resulting in limited bioavailability and erratic absorption. Hence, the aim of this study was to generate a glycerosomal in situ gel of sulpiride for intranasal administration, specifically targeting children with schizophrenia who may have difficulty swallowing traditional solid medications, for enhancing its bioavailability. This study aimed to demonstrate the efficacy of

APA, Harvard, Vancouver, ISO, and other styles

19

Kruchenko, ZhO, and NO Pil'kevych. "Influence of intranasal administration of dopamine on realization of cognitive processes and locomotor activity of rats during stress." Fiziolohichnyĭ zhurnal 59, no. 5 (2013): 56–60. http://dx.doi.org/10.15407/fz59.05.056.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Castellani, Stefano, Giorgia Natalia Iaconisi, Francesca Tripaldi, et al. "Dopamine and Citicoline-Co-Loaded Solid Lipid Nanoparticles as Multifunctional Nanomedicines for Parkinson’s Disease Treatment by Intranasal Administration." Pharmaceutics 16, no. 8 (2024): 1048. http://dx.doi.org/10.3390/pharmaceutics16081048.

Full text

Abstract:

This work aimed to evaluate the potential of the nanosystems constituted by dopamine (DA) and the antioxidant Citicoline (CIT) co-loaded in solid lipid nanoparticles (SLNs) for intranasal administration in the treatment of Parkinson disease (PD). Such nanosystems, denoted as DA-CIT-SLNs, were designed according to the concept of multifunctional nanomedicine where multiple biological roles are combined into a single nanocarrier and prepared by the melt emulsification method employing the self-emulsifying Gelucire® 50/13 as lipid matrix. The resulting DA-CIT-SLNs were characterized regarding par

APA, Harvard, Vancouver, ISO, and other styles

21

de Souza Silva, M. A., C. Mattern, R. H�cker, C. Tomaz, J. P. Huston, and R. K. W. Schwarting. "Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: On the role of benserazide pretreatment." Synapse 27, no. 4 (1997): 294–302. http://dx.doi.org/10.1002/(sici)1098-2396(199712)27:4<294::aid-syn3>3.0.co;2-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Katamesh, Ahmed A., Hend Mohamed Abdel-Bar, Mohammed Khaled Bin Break та ін. "Tailored Intranasal Albumin Caged Selegiline-α Synuclein siRNA Liposome with Improved Efficiency in Parkinson’s Model". Pharmaceutics 17, № 2 (2025): 243. https://doi.org/10.3390/pharmaceutics17020243.

Full text

Abstract:

Background/Objectives: Parkinson’s disease (PD) is a progressive neuro-degenerative disorder characterized by α-synuclein aggregation, which promotes neuronal death and accelerates neurodegeneration. Small interfering RNA (siRNA) can reduce α-synuclein levels, but its therapeutic potential is limited by poor stability and delivery challenges. Similarly, Selegiline (Sel), a monoamine oxidase-B (MAO-B) inhibitor, has low bioavailability, restricting its effectiveness. This study aims to develop an intranasal (IN) albumin-coated liposomal system (C-LipSel-siSNCA2) for the co-delivery of Sel and α

APA, Harvard, Vancouver, ISO, and other styles

23

Talbot, Teddy, Claudia Mattern, Maria Angelica de Souza Silva, and Marcus Lira Brandão. "Intranasal administration of dopamine attenuates unconditioned fear in that it reduces restraint-induced ultrasound vocalizations and escape from bright light." Journal of Psychopharmacology 31, no. 6 (2017): 682–90. http://dx.doi.org/10.1177/0269881116686882.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Kakad*, Smita P., Yash R. Bharati, Sanjay J. Kshirsagar, et al. "Fabrication of Amisulpride Nanosuspension for Nose to Brain Delivery in the Potential Antipsychotic Treatment." Biosciences Biotechnology Research Asia 21, no. 1 (2024): 109–21. http://dx.doi.org/10.13005/bbra/3207.

Full text

Abstract:

ABSTRACT: Background: This research was aimed with the development of antipsychotic drug delivery for olfactory administration which could deliver drug to the brain. Amisulpride is a psychoactive drug that belongs to the benzamide derivatives class. It enhances dopaminergic neurotransmission by inhibiting presynaptic dopamine D2/D3 auto receptors selectively at lower dosages. Method: The nanosuspension was prepared by media milling technique for nose to brain delivery. The nose to brain delivery developed an effective route to bypass the BBB and deliver the drug to the brain. Factorial design

APA, Harvard, Vancouver, ISO, and other styles

25

Abdallah, Marwa H., Mona M. Shahien, Hemat El-Sayed El-Horany, et al. "Evaluation of Mucoadhesive Nano-Bilosomal In Situ Gels Containing Anti-Psychotic Clozapine for Treatment of Schizophrenia: In Vitro and In Vivo Studies." Pharmaceuticals 17, no. 10 (2024): 1404. http://dx.doi.org/10.3390/ph17101404.

Full text

Abstract:

Background/Objectives: Patients with schizophrenia have significant challenges in adhering to and complying with oral medicines, resulting in adverse consequences such as symptom worsening and psychotic relapse. Methods: This study aimed to develop clove oil-based bilosomes using definitive screening design (DSD) to maximize the anti-schizophrenic action of clozapine and promote its nose-to-brain delivery. The target was to optimize the physicochemical properties of bilosomes and incorporate them into mucoadhesive intranasal in situ gels, searching for augmented ex vivo and in vivo clozapine d

APA, Harvard, Vancouver, ISO, and other styles

26

Lewicky, Jordan D., Nya L. Fraleigh, Alexandrine L. Martel, et al. "Improving the Utility of a Dynorphin Peptide Analogue Using Mannosylated Glycoliposomes." International Journal of Molecular Sciences 22, no. 15 (2021): 7996. http://dx.doi.org/10.3390/ijms22157996.

Full text

Abstract:

Peptide therapeutics offer numerous advantages in the treatment of diseases and disorders of the central nervous system (CNS). However, they are not without limitations, especially in terms of their pharmacokinetics where their metabolic lability and low blood–brain barrier penetration hinder their application. Targeted nanoparticle delivery systems are being tapped for their ability to improve the delivery of therapeutics into the brain non-invasively. We have developed a family of mannosylated glycoliposome delivery systems for targeted drug delivery applications. Herein, we demonstrate via

APA, Harvard, Vancouver, ISO, and other styles

27

De Souza Silva, M. A., C. Mattern, R. Häcker, P. J. C. Nogueira, J. P. Huston, and R. K. W. Schwarting. "Intranasal Administration of the Dopaminergic Agonists l-DOPA, Amphetamine, and Cocaine Increases Dopamine Activity in the Neostriatum: A Microdialysis Study in the Rat." Journal of Neurochemistry 68, no. 1 (2002): 233–39. http://dx.doi.org/10.1046/j.1471-4159.1997.68010233.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Lebedev, Andrei A., Yulia N. Bessolova, Nikolay S. Efimov, et al. "Lateral hypothalamic self-stimulation with threshold current intensity induces emotional overeating in self-deprivation paradigm in well-fed rats: Role of orexin and dopaminergic systems of the brain." Reviews on Clinical Pharmacology and Drug Therapy 19, no. 4 (2021): 421–29. http://dx.doi.org/10.17816/rcf194421-429.

Full text

Abstract:

BACKGROUND: Emotional overeating in forms of соmpulsive overeating, or bulimia nervosa, and binge eating disorder (ВED) is underlying the basis of eating disorders. In particular, binge eating disorder is included in ICD-10 as a form of nonchemical dependence. AIM: The participation of the orexin and dopamine systems of the brain was studied in conditions of food self-deprivation caused by self-stimulation of the lateral hypothalamus. METHODS: To reproduce the self-stimulation of the lateral hypothalamus, male Wistar rats were trained to press the pedal in Skinner box. After traini

APA, Harvard, Vancouver, ISO, and other styles

29

Mustafa, Gulam, Niyaz Ahmad, Sanjula Baboota, Javed Ali, and Alka Ahuja. "UHPLC/ESI-Q-TOF-MS method for the measurement of dopamine in rodent striatal tissue: A comparative effects of intranasal administration of ropinirole solution over nanoemulsion." Drug Testing and Analysis 5, no. 8 (2012): 702–9. http://dx.doi.org/10.1002/dta.1426.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Грудень, М. А., Т. В. Давыдова, В. С. Кудрин, et al. "Neuroprotective effects of glutamate antibodies on memory impairment induced by proinflamatory S100A9 protein oligomers in aging animals." ZHurnal «Patologicheskaia fiziologiia i eksperimental`naia terapiia», no. 4(61) (December 19, 2017): 13–20. http://dx.doi.org/10.25557/igpp.2017.4.8518.

Full text

Abstract:

Цель исследования - изучение эффектов хронического интраназального введения антител к глутамату совместно с полученными in vitro олигомерами провоспалительного белка S100A9 на процесс воспроизведения пространственной памяти, а также на содержание нейромедиаторных аминокислот и биогенных аминов в релевантных структурах мозга - гиппокампе и префронтальной коре у 12-месячных мышей С57Bl/6. Методика. В поведенческих экспериментах у всех животных проводили выработку условного рефлекса пассивного избегания и тестировали воспроизведение памятного следа, после этого в нейрохимическом исследовании в ги

APA, Harvard, Vancouver, ISO, and other styles

31

Karpova, Inessa V., Eugenii R. Bychkov, Ilia Yu Tissen, Andrei A. Lebedev, and Petr D. Shabanov. "The effect of the ghrelin receptors inhibitor [D-Lys3]-GHRP-6 on the levels and metabolism of monoamines in symmetric brain areas of rats treated chronically with alcohol." Reviews on Clinical Pharmacology and Drug Therapy 15, no. 3 (2017): 48–56. http://dx.doi.org/10.17816/rcf15348-56.

Full text

Abstract:

Aim. In the course of the study, the impact of the ghrelin receptor GHS-R1a on the condition of symmetric monoaminergic systems of the rat brain was investigated. In particular, it was intended to find out whether the treatment with the ghrelin receptor antagonist [D-Lys3]-GHRP-6, recover the original content of monoamines and their metabolites in the brain of chronic alcoholic rats. Methods. The experiments were performed on 22 Wistar male rats. Experimental animals instead of drinking water received 10 % ethanol solution. Rats of the control groups continued to consume tap water. 6 mon

APA, Harvard, Vancouver, ISO, and other styles

32

Suzuki, Naoto, Takanori Kanazawa, Toyofumi Suzuki, and Noriyasu Kamei. "Intranasal administration." Drug Delivery System 35, no. 1 (2020): 76–80. http://dx.doi.org/10.2745/dds.35.76.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Gad, Shayne C. "Intranasal Administration." Journal of the American College of Toxicology 13, no. 1 (1994): 76–78. http://dx.doi.org/10.3109/10915819409140657.

Full text

Abstract:

The intranasal route has gained increased popularity in the pharmaceutical industry in recent years, particularly because of the number of new peptide therapeutic agents. This has led to a corresponding increase in both interest in and performance of toxicity (or as they are called in the pharmaceutical industry, safety assessment) studies by this route. This report reviews the considerations specific to the intranasal route: formulations, devices for administration, special safety concerns, and animal models employed.

APA, Harvard, Vancouver, ISO, and other styles

34

Ortega, Rafael, Ala Nozari, William Baker, Sannoor Surani, and Melinda Edwards. "Intranasal Naloxone Administration." New England Journal of Medicine 384, no. 12 (2021): e44. http://dx.doi.org/10.1056/nejmvcm2020745.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Fanciullacci, Marcello. "Intranasal Capsaicin Administration." Cephalalgia 13, no. 2 (1993): 74. http://dx.doi.org/10.1046/j.1468-2982.1993.1302072-3.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Gray, Mary Ann. "Intranasal Administration of Medications." Orthopaedic Nursing 11, no. 6 (1992): 46–47. http://dx.doi.org/10.1097/00006416-199211000-00009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Scheibe, Mandy, Christopher Bethge, Martin Witt, and Thomas Hummel. "Intranasal Administration of Drugs." Archives of Otolaryngology–Head & Neck Surgery 134, no. 6 (2008): 643. http://dx.doi.org/10.1001/archotol.134.6.643.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Tucker, Calvin, Lyn Tucker, and Kyle Brown. "The Intranasal Route as an Alternative Method of Medication Administration." Critical Care Nurse 38, no. 5 (2018): 26–31. http://dx.doi.org/10.4037/ccn2018836.

Full text

Abstract:

Intranasal drug administration is a less invasive method of drug delivery that is easily accessible for adult and pediatric patients. Medications administered by the intranasal route have efficacy comparable to intravenous administration and typically have superior efficacy to subcutaneous or intramuscular routes. The intranasal route is beneficial in emergent situations when the intravenous route is not available. The intranasal route is safe and effective in various indications, and therapeutic systemic concentrations of medication can be attained via this route. As the evidence for and comf

APA, Harvard, Vancouver, ISO, and other styles

39

Nardi-Hiebl, S., J. W. Ndieyira, Y. Al Enzi, et al. "Pharmacokinetic Characterisation and Comparison of Bioavailability of Intranasal Fentanyl, Transmucosal, and Intravenous Administration through a Three-Way Crossover Study in 24 Healthy Volunteers." Pain Research and Management 2021 (November 29, 2021): 1–11. http://dx.doi.org/10.1155/2021/2887773.

Full text

Abstract:

Background. For more than 60 years, the synthetic opioid fentanyl has been widely used in anaesthesia and analgesia. While the intravenous formulation is primarily used for general anaesthesia and intensive care settings, the drug’s high lipophilic properties also allow various noninvasive routes of administration. Published data suggest that intranasal administration is also attractive for use as intranasal patient-controlled analgesia (PCA). A newly developed intranasal fentanyl formulation containing 47 μg fentanyl, intravenous fentanyl, and oral transmucosal fentanyl citrate were character

APA, Harvard, Vancouver, ISO, and other styles

40

Eyles, Jim E., E. Diane Williamson, and H. Oya Alpar. "Intranasal Administration of Influenza Vaccines." BioDrugs 13, no. 1 (2000): 35–59. http://dx.doi.org/10.2165/00063030-200013010-00005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Calligaris, Lorenzo, Zanon Davide, Maestro Alessandra, Romina De Bortoli, Antonio Chiaretti, and Egidio Barbi. "Concentrated Midazolam for Intranasal Administration." Pediatric Emergency Care 27, no. 3 (2011): 245–47. http://dx.doi.org/10.1097/pec.0b013e31820db93b.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Suzuki, Naoto, Hiroaki Tanigawa, Taiki Nagatomo, et al. "Utility of a Novel Micro-Spraying Device for Intranasal Administration of Drug Solutions to Mice." Pharmaceutics 15, no. 11 (2023): 2553. http://dx.doi.org/10.3390/pharmaceutics15112553.

Full text

Abstract:

Intranasal administration has attracted attention as a means of delivering drugs because it bypasses the blood–brain barrier. However, conventional intranasal administration of drug solutions to mice using the micropipette method (MP method) is complicated and time-consuming because it requires small doses to be administered under inhalation anesthesia. This study evaluated the effectiveness of a novel intranasal administration method using Micro FPS™, a novel micro-spraying device (the MSD method). The MSD method allowed more reliable administration of the solution to the nasal mucosa than th

APA, Harvard, Vancouver, ISO, and other styles

43

Kurano, Takumi, Takanori Kanazawa, Shingo Iioka, Hiromu Kondo, Yasuhiro Kosuge, and Toyofumi Suzuki. "Intranasal Administration of N-acetyl-L-cysteine Combined with Cell-Penetrating Peptide-Modified Polymer Nanomicelles as a Potential Therapeutic Approach for Amyotrophic Lateral Sclerosis." Pharmaceutics 14, no. 12 (2022): 2590. http://dx.doi.org/10.3390/pharmaceutics14122590.

Full text

Abstract:

Intranasal administration is a promising route for direct drug delivery to the brain; its combination with nanocarriers enhances delivery. We have previously shown that intranasal administration combined with PEG-PCL-Tat (a nanocarrier) efficiently delivers drugs to the brain and exhibits excellent therapeutic efficacy against brain diseases. We aimed to clarify whether intranasal administration combined with PEG-PCL-Tat represents a useful drug delivery system (DDS) for amyotrophic lateral sclerosis (ALS) pharmacotherapy. We used N-acetyl-L-cysteine (NAC) as a model drug with low transferabil

APA, Harvard, Vancouver, ISO, and other styles

44

Ferreira, V., M. Velloso, and M. Landoni. "Bioavailability of butorphanol after intranasal administration to horses." BULGARIAN JOURNAL OF VETERINARY MEDICINE 23, no. 4 (2020): 443–47. http://dx.doi.org/10.15547/bjvm.2019-0051.

Full text

Abstract:

The aim of the present study was to describe butorphanol pharmacokinetics and bioavailability following intranasal administration to horses. Six adult horses received 0.05 mg/kg butorphanol, in a randomised crossover design, by either intravenous or intranasal route. Plasma concentrations of butorphanol were measured at predetermined time points using liquid chromatography/mass spectrometry assay. After intravenous injection, mean ±SD butorphanol steady-state volume of distribution and clearance was 3.20 ± 1.77 l/kg and 3.18 ± 1.47 L/kg/h, respectively. Terminal half-lives for butorphanol afte

APA, Harvard, Vancouver, ISO, and other styles

45

Litvinova, Mariya V., Eugenii R. Bychkov, Andrei A. Lebedev, Nikolay A. Arseniev, and Petr D. Shabanov. "Application of the intranasal road of administration for delivery of drugs to the central nervous system." Reviews on Clinical Pharmacology and Drug Therapy 20, no. 3 (2022): 281–88. http://dx.doi.org/10.17816/rcf203281-288.

Full text

Abstract:

BACKGROUND: The development of effective drug delivery to the central nervous system still remains an important problem in pharmacology despite the rapid development of a large number of new treatment strategies in recent years. Recently interest of the intranasal method as delivery route has greatly increased because this method of administration allows to bypass the blood-brain barrier. There is not a single fundamental study comparing intranasal, central and peripheral methods of administration in order to determine the feasibility of using the intranasal route for delivering substances to

APA, Harvard, Vancouver, ISO, and other styles

46

Fishbein, Mark, Ralph A. Lugo, Jennifer Woodland, Barbara Lininger, and Tom Linscheid. "Evaluation of Intranasal Midazolam in Children Undergoing Esophagogastroduodenoscopy." Journal of Pediatric Gastroenterology and Nutrition 25, no. 3 (1997): 261–66. http://dx.doi.org/10.1002/j.1536-4801.1997.tb01746.x.

Full text

Abstract:

Background:Intravenous midazolam and opioids are used to produce conscious sedation in children undergoing esophagogastroduodenoscopy (EGD). However, children may experience significant fear and anxiety before receiving these medications, especially during separation from parents and during venipuncture. Intranasal administration of midazolam represents a noninvasive method of sedating children before anxiety‐producing events. The objective of this study was to determine whether premedication with intranasal midazolam reduces stress and anxiety of separation from parents and of undergoing veni

APA, Harvard, Vancouver, ISO, and other styles

47

Pesic, Marija, Frank Schippers, Rob Saunders, Lyn Webster, Martin Donsbach, and Thomas Stoehr. "Pharmacokinetics and pharmacodynamics of intranasal remimazolam—a randomized controlled clinical trial." European Journal of Clinical Pharmacology 76, no. 11 (2020): 1505–16. http://dx.doi.org/10.1007/s00228-020-02984-z.

Full text

Abstract:

Abstract Purpose Remimazolam is a novel and ultra-short-acting sedative currently developed for intravenous use in procedural sedation, general anesthesia, and ICU sedation. However, intravenous administration is not always appropriate, depending on the patient or setting. This study evaluated intranasal administration as a potential alternative route. Methods The study used a randomized, double-blind, 9 period cross-over design to compare the pharmacokinetics, pharmacodynamics, and safety of single intranasal doses of 10, 20, and 40 mg remimazolam (as powder or solution) with intranasal place

APA, Harvard, Vancouver, ISO, and other styles

48

Webster, Lynn R., Carmela Pantaleon, Matthew Iverson, Michael D. Smith, Eric R. Kinzler, and Stefan Aigner. "Intranasal Pharmacokinetics of Morphine ARER, a Novel Abuse-Deterrent Formulation: Results from a Randomized, Double-Blind, Four-Way Crossover Study in Nondependent, Opioid-Experienced Subjects." Pain Research and Management 2018 (2018): 1–10. http://dx.doi.org/10.1155/2018/7276021.

Full text

Abstract:

Objective. To investigate the pharmacokinetics (PK) of Morphine ARER, an extended-release (ER), abuse-deterrent formulation of morphine sulfate after oral and intranasal administration. Methods. This randomized, double-blind, double-dummy, placebo-controlled, four-way crossover study assessed the PK of morphine and its active metabolite, M6G, from crushed intranasal Morphine ARER and intact oral Morphine ARER compared with crushed intranasal ER morphine following administration to nondependent, recreational opioid users. The correlation between morphine PK and the pharmacodynamic parameter of

APA, Harvard, Vancouver, ISO, and other styles

49

Cooper, Isabelle, Cornelia B. Landersdorfer, Ashley Gordon St John, and Andis Graudins. "The pharmacokinetics of intranasal droperidol in volunteers characterised via population modelling." SAGE Open Medicine 6 (January 2018): 205031211881328. http://dx.doi.org/10.1177/2050312118813283.

Full text

Abstract:

Background: Droperidol is used parenterally to treat nausea and vomiting, migraine and acute behavioural disturbance. Intranasal use is not reported for droperidol. Intranasal drug administration reduces need for intravenous line placement and risk of needle-stick. Objective: To model population pharmacokinetics of intranasal droperidol. Method: Single doses of intranasal and intravenous droperidol (0.02 mg/kg) were studied in an open-label crossover-trial in seven volunteers with a 1-week washout period. Blood samples collected over 10-h were analysed by liquid chromatography tandem mass spec

APA, Harvard, Vancouver, ISO, and other styles

50

Dietrich, Eric, and John G. Gums. "Intranasal Fentanyl Spray: A Novel Dosage Form for the Treatment of Breakthrough Cancer Pain." Annals of Pharmacotherapy 46, no. 10 (2012): 1382–91. http://dx.doi.org/10.1345/aph.1r069.

Full text

Abstract:

Objective: To review the pharmacology, pharmacokinetics, clinical efficacy, adverse events, dosing, and administration of intranasal fentanyl spray in the treatment of breakthrough cancer pain (BTCP) in adults. Data Sources: Relevant published data were identified using PubMed from inception to April 2012 using the search terms fentanyl nasal spray, intranasal fentanyl, intranasal fentanyl cancer pain, and fentanyl pectin cancer pain. Only articles evaluating the use of intranasal fentanyl spray for cancer pain were selected. Study Selection and Data Extraction: All articles evaluating the pha

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!